Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-01-08 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
可转换公司债券持有人会议规则
Governance Information Classification · 95% confidence The document is titled as "Convertible Corporate Bondholders Meeting Rules" for Zhejiang Tailin Biotechnology Co., Ltd. It details the rules and procedures for meetings of holders of convertible bonds issued by the company, including rights and obligations of bondholders, meeting convening, voting procedures, and legal compliance. There is no financial data, earnings information, or report publication mentioned. The document is a governance-related rulebook specifically for bondholder meetings, which fits best under Governance Information (CGR) as it details internal rules and governance practices related to convertible bondholder meetings.
2021-01-08 Chinese
关于向不特定对象发行可转换公司债券预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding a proposal to issue convertible bonds to unspecified investors. It mentions the board meeting approving the proposal and references the disclosure of the proposal on a regulatory website. The document explicitly states that this announcement does not represent approval or confirmation by regulatory authorities and that the issuance is subject to shareholder and regulatory approvals. The document is short (655 characters) and serves as a notification or update about a financing activity rather than the detailed financing report itself. Therefore, it fits the category of a Capital/Financing Update (CAP).
2021-01-08 Chinese
关于前次募集资金使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Zhejiang Tailin Biotechnology Co., Ltd., including amounts raised, storage, usage, changes in investment projects, and investment benefits. It references regulatory requirements from the China Securities Regulatory Commission and includes financial figures and project details up to September 30, 2020. The content focuses on the specific use and management of capital raised in a prior fundraising event, which aligns with the definition of a Capital/Financing Update (CAP) as it provides updates on fundraising and capital usage. The document is substantive and not merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2021-01-08 Chinese
关于投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the investment to establish a wholly-owned subsidiary. It includes details about the subsidiary, the board resolution approving the investment, and the strategic rationale. There are no financial statements or detailed financial performance data. The document is a corporate announcement about a board-approved investment decision, not a financial report or regulatory filing of financial results. It fits best under Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes through establishing a new subsidiary. The document length is short and focused on the investment announcement, not a full report or regulatory filing.
2021-01-08 Chinese
安信证券股份有限公司关于公司变更部分首次公开发行股票募集资金用途的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the change in the use of funds raised from the company's initial public offering (IPO). It references regulatory approvals, specific fundraising amounts, project investment plans, and compliance with stock exchange rules. The document is not a full annual or interim financial report, nor is it a simple announcement. It is a formal verification and opinion report related to the use of IPO proceeds, which aligns with the category of Capital/Financing Update (CAP) as it deals with fundraising and capital usage changes. The document length is sufficient and contains substantive content about the fundraising and its usage changes, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-01-08 Chinese
关于使用闲置募集资金与自有资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the maturity and redemption of cash management products purchased using idle raised funds and own funds. It details the amounts, dates, and returns of these financial products and references previous announcements about the use of idle funds for cash management. The document is relatively short (2732 characters) and primarily provides an update on the status of these investments, including the full redemption of principal and income. It does not contain comprehensive financial statements, management discussion, or detailed financial results. It is not a full financial report but rather a specific update on financing activities related to cash management and fund usage. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-12-31 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.